AMERICAN SOCIETY OF ADDICTION MEDICINE

Advocated for increased FY27 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY27 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for introduction of Residential Recovery for Seniors Act (H.R.9538). This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs. Advocated for introduction of S. 4941 - the Modernizing Opioid Treatment Access Act 2.0, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Joined coalition letter raising concerns that new draft guidance from the Food and Drug Administration (FDA) could lead to the authorization of more flavored products that have historically appealed to youth. Met with Centers for Medicare & Medicaid Services (CMS) regarding updates to Medicare payment and coding policies for outpatient substance use disorder (SUD) treatment to reflect advances in treatment standards, as well as CMS' CRUSH initiative. Met with SAMHSA regarding clinical policy support and methadone integration

Advocated for increased FY27 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY27 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for introduction of Residential Recovery for Seniors Act (H.R.9538). This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs. Advocated for introduction of S. 4941 - the Modernizing Opioid Treatment Access Act 2.0, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Joined coalition letter raising concerns that new draft guidance from the Food and Drug Administration (FDA) could lead to the authorization of more flavored products that have historically appealed to youth. Met with Centers for Medicare & Medicaid Services (CMS) regarding updates to Medicare payment and coding policies for outpatient substance use disorder (SUD) treatment to reflect advances in treatment standards, as well as CMS' CRUSH initiative. Met with SAMHSA regarding clinical policy support and methadone integration

Advocated for increased FY27 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY27 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for introduction of Residential Recovery for Seniors Act (H.R.9538). This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs. Advocated for introduction of S. 4941 - the Modernizing Opioid Treatment Access Act 2.0, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Joined coalition letter raising concerns that new draft guidance from the Food and Drug Administration (FDA) could lead to the authorization of more flavored products that have historically appealed to youth. Met with Centers for Medicare & Medicaid Services (CMS) regarding updates to Medicare payment and coding policies for outpatient substance use disorder (SUD) treatment to reflect advances in treatment standards, as well as CMS' CRUSH initiative. Met with SAMHSA regarding clinical policy support and methadone integration

Advocated for increased FY27 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY27 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for introduction of Residential Recovery for Seniors Act (H.R.9538). This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs. Advocated for introduction of S. 4941 - the Modernizing Opioid Treatment Access Act 2.0, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Joined coalition letter raising concerns that new draft guidance from the Food and Drug Administration (FDA) could lead to the authorization of more flavored products that have historically appealed to youth. Met with Centers for Medicare & Medicaid Services (CMS) regarding updates to Medicare payment and coding policies for outpatient substance use disorder (SUD) treatment to reflect advances in treatment standards, as well as CMS' CRUSH initiative. Met with SAMHSA regarding clinical policy support and methadone integration

Advocated for increased FY27 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY27 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for introduction of Residential Recovery for Seniors Act (H.R.9538). This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs. Advocated for introduction of S. 4941 - the Modernizing Opioid Treatment Access Act 2.0, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Joined coalition letter raising concerns that new draft guidance from the Food and Drug Administration (FDA) could lead to the authorization of more flavored products that have historically appealed to youth. Met with Centers for Medicare & Medicaid Services (CMS) regarding updates to Medicare payment and coding policies for outpatient substance use disorder (SUD) treatment to reflect advances in treatment standards, as well as CMS' CRUSH initiative. Met with SAMHSA regarding clinical policy support and methadone integration

Advocated for increased FY27 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY27 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for introduction of Residential Recovery for Seniors Act (H.R.9538). This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs. Advocated for introduction of S. 4941 - the Modernizing Opioid Treatment Access Act 2.0, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Joined coalition letter raising concerns that new draft guidance from the Food and Drug Administration (FDA) could lead to the authorization of more flavored products that have historically appealed to youth. Met with Centers for Medicare & Medicaid Services (CMS) regarding updates to Medicare payment and coding policies for outpatient substance use disorder (SUD) treatment to reflect advances in treatment standards, as well as CMS' CRUSH initiative. Met with SAMHSA regarding clinical policy support and methadone integration